Storia in 2 fonti

Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward'

Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward Phase 3 talks with the FDA.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo9 g fa

Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward'

Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward Phase 3 talks with the FDA.

originale

biopharmadive.com10 g fa

Alumis’ TYK2 drug fails in key lupus study

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

Leggi questa versione → originale

Timeline cronologica

martedì 1 settembre 2026·biopharmadive.com
Alumis’ TYK2 drug fails in key lupus study
Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.
martedì 1 settembre 2026·endpoints.news
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward'
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward Phase 3 talks with the FDA.